PD-L1-positive DLBCL was associated with inferior clinical outcome when treated with a rituximab-containing regimen, but showed clinical response to PD-1 blockade therapy, indicating that PD-1 can be a pharmacological target in this disease subtype [48,54]. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.